University of Hyderabad 
Hyderabad

COVID-19: Hyderabad University, CCMB tie up for antibody therapy

Horse-based antibodies have been used earlier for developing antibody therapy for a variety of life-threatening pathologies in humans as anti-venoms, anti-toxins and anti-virals.

From our online archive

HYDERABAD: The University of Hyderabad (UoH) and Centre for Cellular and Molecular Biology (CCMB) have teamed with a startup incubated at the UoH, namely Vins Bioproducts Ltd, in a collaborative project to develop antibody fragment-based therapy against Covid-19.

They plan to use antibody fragments, synthesised from the antibodies generated in horses, offered by the F(ab’)2 platform technology. 

Horse-based antibodies have been used earlier for developing antibody therapy for a variety of life-threatening pathologies in humans as anti-venoms, anti-toxins and anti-virals.

The antibodies, raised in horses using inactivated Coronavirus is fractionated and purified to produce antibody fragments F(ab’)2 for neutralising Coronavirus in the patients for recovery.

While the UoH team is headed by Dr Nooruddin Khan, Associate Professor at the Department of Animal Biology, the team at CCMB is headed by Dr Krishnan Harinivas, a principal scientist.

India's aspirations no longer limited to its borders: PM Modi tells diaspora at The Hague

'Why doesn't the PM work from home?' Punjab CM slams Modi's foreign visits amid austerity call

NCB for the first time in India seizes Captagon drug worth Rs 182 crore

UDF begins cabinet talks ahead of swearing-in amid portfolio tussle

'I have nothing to hide': Robert Vadra slams ED after bail in land deal-linked PMLA case

SCROLL FOR NEXT